Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| primate origin | 5740 | 2096328-94-6 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Pozelimab-bbfg is a human, monoclonal immunoglobulin G4P (IgG4P) antibody directed against the terminal complement protein C5 that inhibits terminal complement activation by blocking cleavage of C5 into C5a (anaphylatoxin) and C5b, thereby blocking the formation of the membrane-attack complex (C5b-C9, a structure mediating cell lysis).
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 18, 2023 | FDA | REGENERON PHARMACEUTICALS |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L04AJ11 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Complement inhibitors |
| FDA EPC | N0000175575 | Complement Inhibitor |
| FDA MoA | N0000175974 | Complement Inhibitors |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| CHAPLE disease | indication | 1279887007 | |
| Meningococcal infectious disease | contraindication | 23511006 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Complement C5 | Secreted | INHIBITOR | Kd | 9.72 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| CHEBI:757505 | CHEBI |
| CHEMBL4298086 | ChEMBL_ID |
| C000731768 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12900 | IUPHAR_LIGAND_ID |
| DB15218 | DRUGBANK_ID |
| 4042758 | VANDF |
| 4042759 | VANDF |
| C5139913 | UMLSCUI |
| 10945 | INN_ID |
| 370431 | MMSL |
| 41916 | MMSL |
| d10098 | MMSL |
| 019529 | NDDF |
| D11477 | KEGG_DRUG |
| 0JJ21K6L2I | UNII |
| 2663938 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| VEOPOZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61755-014 | INJECTION, SOLUTION | 200 mg | SUBCUTANEOUS | BLA | 29 sections |